CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Onivyde for Metastatic Pancreatic Cancer – Details

Project Number PC0107-000
Brand Name Onivyde
Generic Name Irinotecan Liposome
Strength 4.3 mg/mL
Tumour Type Gastrointestinal
Indication Metastatic Pancreatic Cancer
Funding Request For the treatment of metastatic adenocarcinoma of the pancreas in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in adult patients who have been previously treated with gemcitabine-based therapy
Review Status Complete
Pre Noc Submission Yes
NOC Date August 9, 2017
Manufacturer Shire Canada
Sponsor Shire Canada
Clarification As per Section 4.1.1 subsection a) of the pCODR Procedures, the timeline of the review was temporarily stopped pending rescheduling of the Checkpoint Meeting, as per the request of Shire Canada Inc.
Submission Date April 27, 2017
Submission Deemed Complete May 4, 2017
Submission Type Initial
Prioritization Requested Requested and Not Granted
Stakeholder Input Deadline ‡ May 11, 2017
Check-point meeting July 12, 2017
pERC Meeting October 19, 2017
Initial Recommendation Issued November 2, 2017
Feedback Deadline ‡ November 16, 2017
pERC Reconsideration Meeting December 14, 2017
Final Recommendation Issued January 5, 2018
Notification to Implement Issued January 22, 2018
Therapeutic Area Metastatic Pancreatic Cancer
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.